Tumor antigen-specific T cell response via antigen-presenting cells

Tumor antigen-specific T cell responses via antigen-presenting cells (APCs), particularly dendritic cells (DCs), represent a fundamental mechanism of the adaptive immune system's anti-tumor activity. This process, often referred to as the 'Cancer-Immunity Cycle,' involves the uptake of tumor-associated antigens by DCs, followed by their processing and presentation on Major Histocompatibility Complex (MHC) molecules to T cell receptors (Chen & Mellman, 2013). Successful activation requires secondary co-stimulatory signals and cytokine support to transform naive T cells into effector cytotoxic T lymphocytes capable of recognizing and lysing malignant cells (Wculek et al., 2020). In the context of oncology, this pathway is the primary target of therapeutic cancer vaccines, such as Sipuleucel-T, and is a critical component of the efficacy of immune checkpoint inhibitors (Gardner & Ruffell, 2016). While not a single molecular target, it encompasses a complex network of receptors and signaling molecules that are modulated to overcome tumor-induced immune evasion. Understanding this response is vital for developing immunotherapies that can effectively prime the immune system against diverse tumor neoantigens.

Other names

Antigen presentationDendritic cell-mediated T cell activationCancer-immunity cycleCross-presentationTumor-specific immune response

The mechanism involves the 'Cancer-Immunity Cycle' where dendritic cells (DCs) capture tumor-associated antigens (TAAs), undergo maturation, and migrate to lymph nodes to present these antigens via MHC molecules to T cells. This interaction, supported by co-stimulatory molecules (e.g., CD80, CD86) and cytokines (e.g., IL-12), leads to the clonal expansion of tumor-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T cells (Wculek et al., 2020; Chen & Mellman, 2013).